Shuo Qie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4062416/publications.pdf

Version: 2024-02-01

30	1,372	516710 16	552781 26
papers	citations	h-index	g-index

32	32	32	2348
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cyclin D1, cancer progression, and opportunities in cancer treatment. Journal of Molecular Medicine, 2016, 94, 1313-1326.	3.9	477
2	Functional significance of VEGF-a in human ovarian carcinoma: Role in vasculogenic mimicry. Cancer Biology and Therapy, 2008, 7, 758-766.	3.4	92
3	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9298-E9307.	7.1	91
4	Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Human Pathology, 2008, 39, 444-451.	2.0	82
5	ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation. Journal of Cellular Biochemistry, 2014, 115, 498-509.	2.6	75
6	Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nature Communications, 2019, 10, 1296.	12.8	73
7	Carbon Source Metabolism and Its Regulation in Cancer Cells. Critical Reviews in Eukaryotic Gene Expression, 2012, 22, 17-35.	0.9	53
8	RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. PLoS Genetics, 2016, 12, e1006306.	3.5	52
9	Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming. Cell Cycle, 2012, 11, 3679-3690.	2.6	43
10	Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma. Nature Communications, 2017, 8, 1534.	12.8	42
11	PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. PLoS Genetics, 2016, 12, e1006518.	3.5	41
12	Structural insights into E1 recognition and the ubiquitin-conjugating activity of the E2 enzyme Cdc34. Nature Communications, 2019, 10, 3296.	12.8	39
13	Cyclin D degradation by E3 ligases in cancer progression and treatment. Seminars in Cancer Biology, 2020, 67, 159-170.	9.6	37
14	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances, 2019, 5, eaax6352.	10.3	31
15	Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target. Journal of Experimental and Clinical Cancer Research, 2022, 41, 161.	8.6	31
16	Pilot study on the interaction between B16 melanoma cell-line and bone-marrow derived mesenchymal stem cells. Cancer Letters, 2008, 263, 35-43.	7.2	30
17	Stanniocalcin 2 (STC2) expression promotes post-radiation survival, migration and invasion of nasopharyngeal carcinoma cells . Cancer Management and Research, 2019, Volume 11, 6411-6424.	1.9	19
18	Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma. OncoTargets and Therapy, 2018, Volume 11, 3721-3729.	2.0	13

#	Article	IF	Citations
19	Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3. Oncogene, 2021, 40, 292-306.	5.9	13
20	A pilot study on acute inflammation and cancer: a new balance between IFN-Î³ and TGF-Î² in melanoma. Journal of Experimental and Clinical Cancer Research, 2009, 28, 23.	8.6	10
21	Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6. Molecular and Cellular Oncology, 2019, 6, 1610257.	0.7	5
22	Effect of early enteral nutrition on laparoscopic common bile duct exploration with enhanced recovery after surgery protocols. European Journal of Clinical Nutrition, 2019, 73, 1244-1249.	2.9	5
23	Overview of Glutamine Dependency and Metabolic Rescue Protocols. Methods in Molecular Biology, 2019, 1928, 427-439.	0.9	4
24	The E3 Ubiquitin Ligase Fbxo4 Functions as a Tumor Suppressor: Its Biological Importance and Therapeutic Perspectives. Cancers, 2022, 14, 2133.	3.7	4
25	Release the ink4a/arf growth suppression by â€œuâ€•and â€œmeâ€?. Cell Cycle, 2011, 10, 185-190.	2.6	1
26	Glutamine Metabolism in Cancer Cells. , 2018, , .		1
27	Abstract 5143: ErbB2 activation up-regulates glutaminase 1 expression via NF-ÎºB pathway. , 2012, , .		0
28	Abstract LB-135: Stanniocalcin 2 attenuates tumor cell proliferation but suppresses apoptosis in nutrient-deprived conditions.. , 2013, , .		0
29	Abstract 2849: RNA-binding protein FXR1 negatively regulates senescence by destabilizing mRNA CDKN1A and stabilizing noncoding RNA telomerase RNA component. , 2016, , .		0
30	Abstract 3562: A novel TGF-Î² signaling pathway promotes a slow growing phenotype of cancer cells in response to glutamine insufficiency. , 2017, , .		0